Clorox stock has delivered a decline of about 23% over the past five years, yet recent short term gains and a low value score suggest the shares may still be pricing in a premium rather than offering clear value.

• Clorox has fallen 22.9% over five years, which raises the question of whether investors have been paying too much for its earnings and cash flows.
• The planned supply chain gains from Clorox's ongoing ERP transition can support margin efficiency, while any execution issues on that project may weigh on profitability and keep valuation pressure in place.
• Clorox scores 2 out of 6 on the broader valuation checks, which hints that the stock leans expensive rather than looking like an obvious bargain on most measures, even after recent share price weakness. More detail is available in the valuation breakdown on 2 out of 6.

The issue now is whether Clorox's current share price fairly reflects this mixed track record and the expected benefits from its ERP driven supply chain improvements.

Is Clorox Getting Expensive on Earnings?

The P/E multiple suits Clorox because it is a mature consumer products business where earnings are a key anchor for valuation. Clorox currently trades at about 22.0x earnings, compared with a Household Products industry average of roughly 17.6x and a peer average of around 21.3x. That places the stock at a premium to the wider industry and slightly above similar peers.

The fair P/E ratio implied by broader fundamentals is 19.2x, which is below where Clorox trades today. Despite management highlighting expected supply chain gains from the ERP transition, the current P/E still prices Clorox above what this framework suggests is reasonable. The gap between the current and fair multiples indicates investors are paying more for the stock relative to its earnings profile.

On the P/E multiple, Clorox stock currently screens as overvalued compared with both its tailored fair ratio and the wider Household Products industry.

The Clorox Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Clorox pick up where this valuation puzzle leaves off. They explain which assumptions about Clorox's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each one links a fair value to a particular story about the company's potential catalysts and risks, so you can track over time which version of events is actually playing out on the Community page.

Community views on Clorox are split between a more optimistic ERP and GOJO story and a more cautious read on competition and pricing power.

Bull case: 20% undervalued

"The imminent end of the Glad JV with P&G will directly expand gross margins as Clorox fully internalizes profits from this high-volume segment, with an expected multi-year earnings lift and improved capital allocation flexibility..."

Bear case: roughly fairly valued

"Clorox is dealing with heightened price competition and deep discounting in key segments like Glad and Cat Litter, as well as increased promotional intensity from private label and competitors; this could compress net margins and reduce overall earnings as Clorox is forced to defend its market share..."

Do you think there's more to the story for Clorox? Head over to our Community to see what others are saying!

The Bottom Line

Clorox still screens as overvalued on its main earnings multiples, even after a five year period of weaker share price performance. The market is already paying up for the ERP driven supply chain story and for relatively resilient earnings, so there is limited room for disappointment if execution is bumpy. The debate now largely comes down to whether Clorox can translate its operational projects into durable margin gains that justify a premium multiple, or whether the stock eventually settles closer to industry valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.